OliX Pharmaceuticals

OliX Pharmaceuticals, a clinical-stage biopharmaceutical company, was established in Suwon, South Korea, on February 26, 2010, by Dong-Ki Lee. The company's genesis is rooted in Lee's extensive academic and research background; he earned a Ph.D. in Biochemistry from Cornell University and has held professorships in Chemistry, focusing his work on novel siRNA structures and eukaryotic gene regulation. This deep expertise in nucleic acids laid the groundwork for OliX's specialization in RNA interference (RNAi) therapeutics.

The company operates in the biotechnology market, focusing on developing treatments for intractable diseases by silencing disease-causing genes. Its business model centers on the discovery, development, and subsequent out-licensing of its therapeutic candidates to larger pharmaceutical partners for commercialization. This strategy is evidenced by multiple collaboration and licensing agreements, such as a partnership with Hansoh Pharma to develop and commercialize siRNA therapeutics in Greater China, and another with L'Oréal focused on cosmetic applications for skin and hair. These deals provide upfront payments, milestone-based royalties, and leverage the partner's manufacturing and commercialization capabilities, while OliX retains rights in other global markets.

OliX's core technological asset is its proprietary asymmetric siRNA (asiRNA) platform, a gene-silencing technology designed to be highly efficient. Building on this, the company has developed two key therapeutic platforms. The first is cell-penetrating asiRNA (cp-asiRNA), which enables intracellular delivery of the therapeutic agent without a separate delivery system, reducing side effects and allowing for local administration. This platform is aimed at developing treatments for dermal, ophthalmic, and pulmonary diseases such as hypertrophic scars (OLX101A), age-related macular degeneration (AMD), and idiopathic pulmonary fibrosis. The second platform, GalNAc-asiRNA, is engineered to specifically target a variety of liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatitis B.

The company's pipeline includes several programs at various stages of development. Its treatment for hypertrophic scarring entered Phase 2 clinical trials in 2020. Other pipeline candidates address conditions like androgenic alopecia (hair loss), dry and wet AMD, and subretinal fibrosis. OliX became a publicly traded company on the KOSDAQ exchange, which has provided funding for its aggressive development timeline, including the goal to have at least 10 programs in clinical trials by 2025.

Keywords: RNAi therapeutics, siRNA, asymmetric siRNA, asiRNA, gene silencing, clinical-stage biotechnology, Dong-Ki Lee, Suwon, KOSDAQ, dermal diseases, ophthalmic diseases, pulmonary diseases, liver diseases, hypertrophic scars, age-related macular degeneration, idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, cell-penetrating asiRNA, GalNAc-asiRNA, pharmaceutical licensing, drug development, nucleic acid therapeutics, biopharmaceutical, L'Oréal collaboration, Hansoh Pharma partnership